Your session is about to expire
← Back to Search
GZ17-6.02 + Capecitabine for Metastatic Hormone Receptor Positive Breast Cancer (GEN602 Trial)
GEN602 Trial Summary
This trial is testing a new drug, GZ17-6.02, to see if it is safe and works well against advanced solid tumors or lymphoma.
- Cancer
- Stomach Cancer
- Breast Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Sarcoma
- Basal Cell Carcinoma
- Cutaneous T-Cell Lymphoma
- Squamous Cell Carcinoma
- Prostate Cancer
- Solid Tumors
- Head and Neck Squamous Cell Carcinoma
- Lymphoma
GEN602 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowGEN602 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 2 trial • 10 Patients • NCT02000882GEN602 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are allergic or have had bad reactions to capecitabine or 5-FU.You are currently taking any experimental medication.You are currently taking medication called MAOIs.You have tumors that have spread to your brain and require treatment or radiation therapy. You must have stable brain tumors for at least 30 days before starting the study.You are expected to live for at least 3 more months.You are currently taking steroids to manage neurological symptoms.Your tumor has grown after trying standard treatments like chemotherapy, targeted therapy, or immunotherapy. If there is no approved treatment available, if you cannot tolerate the standard treatment, or if you choose not to receive it, you may be eligible.
- Group 1: Experimental: Combination with Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
- Group 2: Experimental: Combination with Capecitabine in Metastatic Colorectal Cancer
- Group 3: Experimental: monotherapy
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What effects can be expected when using GZ17-6.02?
"The safety of GZ17-6.02 has been assigned a score of 1, given that the trial is only in its initial phase and there are limited data points to support both efficacy and safety."
Is there still availability for enrolment in this clinical trial?
"According to clinicialtrials.gov this medical trial is still seeking enrolment from volunteers; its initial posting date was March 1st 2019 and the most recent update happened on May 11th 2022."
What is the current number of enrollees for this trial?
"Verified, clinicaltrials.gov attests to the fact that this trial is actively searching for participants since it was initially posted on March 1st 2019 and last revised on May 11th 2022. Currently, 127 individuals must be enrolled from one site."
Share this study with friends
Copy Link
Messenger